1 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow LM-108: new trials by email Literature Review of LM-108 trials Research Report on LM-108
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours LM-108, Toripalimab - Advanced Solid Tumor | Phase 2 | Not yet recruiting | LaNova Medicines Limited | 84 | 2025-03-26 | 2025-03-13 |
| LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer LM-108, Toripalimab, Eribulin - TNBC - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 74 | 2024-07-10 | 2024-08-02 |
| A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors LM-108, Toripalimab - Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | LaNova Medicines Limited | 392 | 2022-08-26 | 2026-09-03 |
| Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours LM-108, An Anti-PD-1 Antibody - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | LaNova Medicines Limited | 24 | 2022-05-26 | 2023-10-25 |
| Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours LM-108, An Anti-PD-1 Antibody - Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | LaNova Australia Pty Limited | 78 | 2022-03-16 | 2025-09-12 |
Triple Negative Breast Neoplasms (1)
LaNova Medicines Limited (3) · Fudan University (1) · LaNova Australia Pty Limited (1)
China (3) · Australia (1) · United States (1)
Lin Shen (1)